

LUCENCEINSIGHT™

Multi Cancer Early Detection

Early Detection Saves Lives


Physician Brochure

- Traditional screening is recommended only for colorectal, breast, and cervical cancer.¹

- 4 in 5 cancer deaths are not covered by traditional screening.² These arise from unscreened common cancers like lung, liver, and pancreas.




- 5-year survival is higher when cancer is detected early.³



- Lucence**INSIGHT**™ is a multi-cancer early detection (MCED) next-generation sequencing test that screens for up to 50 cancers with a single blood draw.
- The test uses Lucence's amplicon-based mirror barcoding technology to detect circulating tumor and viral DNA. It then predicts tumor location with machine learning.

LucenceINSIGHT™ Screens For Cancers With High Accuracy



Evidence


- LucenceINSIGHT™ reported 100% positive predictive value (PPV) from a prospective real-world cohort of 264 asymptomatic individuals in 2023.⁶
- A performance of 81% sensitivity and 99% specificity was reported from a retrospective cohort of 601 patient samples in 2024.⁴

Case Study: Stage III Colorectal Cancer⁶

A 60 year old asymptomatic male underwent cancer screening.

LucenceINSIGHT™ detected a *RHOA* G62E at 0.4% VAF. PET-CT showed right colon focal uptake (right figure).

Colonoscopy confirmed adenocarcinoma. Subsequent surgery for curative intent confirmed colorectal cancer.



Focal uptake detected in right ascending colon.

Comprehensive screening of 50 cancers in one go.

Head & Neck

Nasopharyngeal cancer (EBV+)
Oropharyngeal cancer
(HPV-positive; HPV-negative)
Laryngeal cancer
Salivary gland cancer

Non-Hodgkin lymphoma

(Burkitt's lymphoma; Diffuse large B-cell lymphoma; Lymphoplasmacytic lymphoma)

Hairy cell leukemia

Breast cancer

Lung cancer

Lung neuroendocrine tumor

Liver cancer

Biliary tract cancer

(Intrahepatic, Extrahepatic, Gallbladder)

Kidney cancer (clear cell)

Adult Wilms tumor

Small intestine cancer

Cervical cancer

Endometrial cancer

Ovarian cancer

Ovarian germ cell & stromal tumors

Vulvar cancer

Soft tissue cancer

(Angiosarcoma; Smooth muscle sarcoma)

Eye cancer

(Conjunctival melanoma; Uveal melanoma)

Esophageal cancer

Thyroid cancer

Acute myeloid leukemia (AML)

(AML, NPM1-mutated; AML, other defined genetic alterations; AML, myelodysplasia-related)

Mast cell tumor

Myeloproliferative neoplasm

Myeloma

Bone cancer

Stomach cancer

Stomach neuroendocrine tumor

Gastrointestinal stromal tumor (GIST)

Adrenal gland cancer

Pancreatic cancer

Colorectal cancer

Colorectal neuroendocrine tumor

Bladder cancer

Penile cancer

Prostate cancer

Testis cancer

Skin cancer

(Melanoma; Non-melanoma)

For Women

Turnaround Time:
(Working Days)


18

LucenceINSIGHT™ 12

covers 12 cancers for women

LucenceINSIGHT™ Women's 7

covers 7 cancers (in pink)



For Men

Turnaround Time:
(Working Days)


18

LucenceINSIGHT™ 12

covers 12 cancers for men

LucenceINSIGHT™ 5

covers 5 cancers (in blue)



Recommendations To Patients

- LucenceINSIGHT™ is recommended for patients who:
 - ✓ are aged 40+.
 - ✓ have elevated risk of cancer (family history, diet, lifestyle)
- The test is not recommended for patients who:
 - ✗ are pregnant
 - ✗ are in cancer remission for < 3 years
 - ✗ had an allogenic bone transplant or a blood transfusion < 2 weeks prior to sample collection
- No fasting is needed. Patient should refrain from heavy meals 4 hours before.

Distributed By Parkway Laboratories

LucenceINSIGHT™ is a screening test to evaluate cancer risk. This test is not intended for use as a diagnostic tool and should not replace the standard of care screening routine or the care of a healthcare provider. Intended for access and use by Singaporean physicians only.

This brochure is not intended for the purpose of providing medical advice. All information, content, and material of this brochure are for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Always seek the advice of your physician or other qualified healthcare provider for information you may need regarding a medical condition.

References:

1. HealthHub. Screen for Life. Singapore Ministry of Health. https://www.healthhub.sg/programmes/screen_for_life/sfl-faqs#home. Accessed October 24 2024.
2. Statistic derived from data reported in Bray, F. et al. CA Cancer J. Clin. 2024; 74(3): 229-263.
3. Statistics derived from data reported in SEER Cancer Stat Facts. <https://seer.cancer.gov/statfacts/>.
4. Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042.
5. Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212-222.
6. Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626

Website



Facebook



Lucence Service Laboratory - Henderson Industrial Park 211 Henderson Road #04-01/02, Singapore 159552

Lucence Diagnostics Pte. Ltd. Is licenced by the Ministry of Health (Singapore) as a Clinical Laboratory (License Number: L/1710039/CLB/003/222) under the Healthcare Services Act 2020. GST Registered 201605840N.

© 2024 Lucence Diagnostics Pte. Ltd. All Rights Reserved

M6001E-SG-06. November 2024